REINSURANCE GROUP OF AMERICA INC

Company Overview

Reinsurance Group of America (RGA) is a global life and health reinsurer and financial‑solutions provider that underwrites traditional reinsurance (individual and group life, health, disability, LTC, critical illness) and asset‑intensive solutions (longevity reinsurance, pension risk transfer, stable value and capital/financial reinsurance). RGA writes business facultatively and by treaty across five regions and sells primarily direct to large, highly rated life insurers; reinsurance in force was reported near $3.9–4.1 trillion in recent filings. The business is capital‑intensive and highly regulated (NAIC/RBC, Bermuda solvency regimes, Solvency II influences and local privacy/cyber rules) and is exposed to actuarial assumption volatility (mortality, morbidity, lapses), interest‑rate and credit market moves, and concentrated counterparty/ceded exposure.

Executive Compensation Practices

Given RGA’s long‑duration liabilities and investment income sensitivity, executive pay is likely calibrated to multi‑year, economic performance measures rather than single‑quarter GAAP earnings — common metrics include adjusted operating income before tax, return on equity, economic net income or adjusted tangible book value, and investment yield/portfolio returns. Filings show management emphasizes adjusted operating income and in‑force management (e.g., reinsurance in force growth, retention increases from $8M to $30M) and these strategic moves (retention, successful PRT transactions, portfolio repositioning) will likely drive long‑term incentive targets and vesting schedules. Expect a heavy mix of equity‑based and deferred compensation to retain specialized actuarial and transaction teams, with malus/clawback and gating tied to capital/rating outcomes (RBC, ECR, regulatory covenant tests) and multi‑year underwriting experience given volatile claim and investment outcomes.

Insider Trading Considerations

Insiders at RGA will frequently possess material nonpublic information about actuarial assumption changes, large single‑premium PRT or longevity transactions, retrocession arrangements, and treaty renewals — trades shortly before filings that disclose remeasurements (e.g., the retention change and $617M repositioning loss) are especially informative. Because capital actions (dividends, debt issuances, unused repurchase authorizations) and rating/covenant exposures materially affect share value, insider sales following stabilization of capital metrics are common, while insider buys can be a stronger signal of confidence given the company’s long liabilities and regulatory constraints. Standard controls apply: SEC Section 16 short‑swing rules, blackout windows around quarterly/annual reports, and widespread use of 10b5‑1 plans; additionally, state and international insurance regulatory considerations (statutory capital and dividend approval) can limit the timing and economic rationale for insider transactions.